Aprea Therapeutics

Aprea Therapeutics (NASDAQ: APRE) is a clinical-stage precision oncology company focused on synthetic-lethality cancer therapeutics that target DNA damage response pathways. Its lead candidate is APR-1051, an orally bioavailable small-molecule WEE1 kinase inhibitor in a Phase 1 dose-escalation trial (ACESOT-1051) for patients with advanced solid tumors and biomarkers, with a second candidate, ATRN-119, an ATR inhibitor in Phase 1/2a development for solid tumors. In its August 12, 2026 Q2 report, management guided that the next clinical data update from ACESOT-1051 is anticipated at a medical meeting in Q4 2026, and an ACESOT-1051 program update noted accelerating enrollment as dose escalation advances. The company is headquartered in Doylestown, Pennsylvania.